Skip to content
DE

LTX-315Investigational cancer therapy

LTX-315 is an investigational peptide designed for injection directly into a tumour. Researchers are exploring whether local cell damage can also stimulate an antitumour immune response.

What is LTX-315?

LTX-315 is an investigational oncolytic peptide designed for injection directly into a tumour. Its development combines local tumour-cell destruction with an attempt to stimulate an antitumour immune response.

How it works

Damage to tumour cells can release material that attracts and activates immune cells. Researchers investigate whether this local response can contribute to wider tumour control.

Effects studied

Tumour destruction and immune-cell infiltration

An early solid-tumour study examined biological activity after injection, including changes in tumour tissue. Cell death and immune infiltration do not by themselves establish longer survival or durable control of cancer elsewhere. 1

Evidence: Early-phase human oncology research.

What does the evidence show?

The archived reference is an early-phase solid-tumour study. Such work can establish biological activity and tolerability without proving a clinical advantage over existing care.

Two ideas in one treatment

An oncolytic treatment aims to damage tumour cells. Material released from those cells may also attract immune cells. LTX-315 was developed to combine local tumour damage with this possible immune response. Clinical evidence is needed to establish each effect.

What early biopsies can show

A biopsy may reveal cell death or a change in immune-cell infiltration after injection. Those findings help researchers understand whether the treatment reached its target. They do not automatically establish control of uninjected tumours, a durable response or a longer life. 1

Why combinations complicate attribution

Trials may pair this approach with other immunotherapies. To attribute a response to the peptide, the study must be able to distinguish its contribution from that of the other treatment. Shrinkage of an injected lesion also needs to be assessed separately from an overall objective response across the patient’s cancer.

Where the practical boundary sits

Intratumoural treatment belongs in oncology research or a specifically authorised clinical context, not self-experimentation. Injection-site effects and systemic reactions require monitoring. A company’s trial announcement or permission to begin a study is not marketing approval. Current programme status needs an updated trial and regulator check. 2

Safety & status

Injection-site and systemic reactions need monitoring in an oncology setting. Permission to conduct a trial is not marketing approval. 2

Country and product status

This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.

Frequently asked questions

Does shrinkage of an injected tumour mean the treatment works throughout the body?

Not necessarily. Local lesion response, response across all tumours and survival are separate outcomes.

Can a response to combination treatment be attributed to LTX-315?

Only if the study design separates its contribution. Other immunotherapies used alongside it may also contribute.

Further reading

Concept illustration for LTX-315.GuideLTX-315: what do we know about this experimental cancer therapy?LTX-315 is injected directly into tumors to destroy tumor cells and trigger an immune response. Early trials suggest activity, but a clinical benefit remains unestablished. It is not approved.Read the article

Sources

This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.

  1. LTX-315: paper 10.1158/1078-0432.CCR-20-3435 Research reference · Retained archive reference; not independently checked for this draft.
  2. LTX-315: verrica.com reference Reference or product information · Retained archive reference; not independently checked for this draft.
Research provenance

This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.